(Bold for FDA approved)
How TRIAZOLAM works• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibitory actions in sleep centers may provide sedative hypnotic effects
• Generally takes effect in less than an hour
Notable Side Effects• Sedation, fatigue, depression
• Dizziness, ataxia, slurred speech, weakness
• Forgetfulness, confusion
• Hyperexcitability, nervousness
• Anterograde amnesia
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
• Rebound insomnia when withdrawing from long-term treatment
Life Threatening Side Effects• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias

unusual

common
• Wait
• To avoid problems with memory, take triazolam only if planning to have a full night’s sleep
• Lower the dose
• Switch to a shorter-acting sedative hypnotic
• Switch to a non-benzodiazepine hypnotic
• Administer flumazenil if side effects are severe or life-threatening
• 0.125–0.25 mg/day at bedtime for 7–10 days
Dosage Forms• Tablet 0.125 mg, 0.25 mg
• Not generally intended for long-term use
• Increased wakefulness during the latter part of the night (wearing off) or an increase in daytime anxiety (rebound) may occur because of short half-life
• Triazolam is a Schedule IV drug
• Some patients may develop dependence and/or tolerance; risk may be greater with higher doses
• History of drug addiction may increase risk of dependence
Renal Impairment• Drug should be used with caution
Hepatic Impairment• Drug should be used with caution
Cardiac Impairment• Benzodiazepines have been used to treat insomnia associated with acute myocardial infarction
Elderly• Recommended initial dose: 0.125 mg
• May be more sensitive to adverse effects
Children and Adolescents• Safety and efficacy have not been established
• Long-term effects of triazolam in children/ adolescents are unknown
• Should generally receive lower doses and be more closely monitored
Pregnancy• Contraindicated for use in pregnancy
• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
Breast Feeding• Unknown if triazolam is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
• Effects on infant have been observed and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera